Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued

Regeneron Pharmaceuticals is rated Sell at $808, with a fair value of ~$675, implying a 16.4% downside risk. Dupixent's growth is strong, but patent expiration in 2031 and biosimilar risks cap long-term upside reflected in today's price. REGN's EYLEA HD gains are offset by legacy product declines; slowing overall franchise erosion is critical for future cash flow projections.

Seeking Alpha • Oct 28, 2026

Regeneron extends US agreement for additional supply of Ebola treatment

Regeneron said on Monday it extended its agreement with a US health authority to ​provide additional supply of its Ebola ‌treatment, amid a growing outbreak in Africa.

Reuters • Oct 26, 2026

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.

24/7 Wall Street • Oct 26, 2026

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million

GlobeNewsWire • Oct 26, 2026

Here's Why Regeneron (REGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Oct 26, 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence

GlobeNewsWire • Oct 25, 2026

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 23, 2026

Regeneron: Is The Market Undervaluing Its Growth Potential

At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.

Seeking Alpha • Oct 22, 2026

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.

The Motley Fool • Oct 19, 2026

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.

The Motley Fool • Oct 17, 2026